{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:05:39Z","timestamp":1785283539006,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0966-4","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T09:12:08Z","timestamp":1544433128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)"],"prefix":"10.1186","volume":"13","author":[{"given":"Alberto","family":"Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Ais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Beaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-7858","authenticated-orcid":false,"given":"Alicia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,10]]},"reference":[{"issue":"1","key":"966_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"key":"966_CR2","doi-asserted-by":"crossref","unstructured":"Simonneau G, Gali\u00e8 N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 SUPPL): 5S-12S.","DOI":"10.1016\/j.jacc.2004.02.037"},{"issue":"1","key":"966_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1183\/09031936.00092306","volume":"30","author":"AJ Peacock","year":"2007","unstructured":"Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104\u20139.","journal-title":"Eur Respir J"},{"key":"966_CR4","doi-asserted-by":"crossref","unstructured":"Humbert M, Ghofrani H-A. The molecular targets of approved treatments for pulmonary arterial hypertension. [cited 2018 Apr 12]; Available from: \n                    http:\/\/thorax.bmj.com\/content\/thoraxjnl\/71\/1\/73.full.pdf","DOI":"10.1136\/thoraxjnl-2015-207170"},{"issue":"118","key":"966_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1183\/09059180.00008010","volume":"19","author":"J-L Vachiery","year":"2010","unstructured":"Vachiery J-L, Simonneau G. Management of severe pulmonary arterial hypertension. Eur Respir Rev. 2010;19(118):279\u201387 [cited 2018 May 14] Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21119186\n                    \n                  .","journal-title":"Eur Respir Rev"},{"issue":"138","key":"966_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1183\/16000617.0067-2015","volume":"24","author":"IM Lang","year":"2015","unstructured":"Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev. 2015;24(138):630\u201341.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"966_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.rmed.2010.12.018","volume":"105","author":"Z Safdar","year":"2011","unstructured":"Safdar Z. Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respir Med. 2011;105(6):818\u201327 [cited 2018 May 14] Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21273054\n                    \n                  .","journal-title":"Respir Med"},{"key":"966_CR8","unstructured":"Terap IDEP, Hap L, Ii-iv CF. Informe de Posicionamiento Terap\u00e9utico de selexipag ( Uptravi \u00ae ) en hipertensi\u00f3n pulmonar. 2017;1\u20136."},{"issue":"26","key":"966_CR9","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"key":"966_CR10","unstructured":"Bayram MM, Walters B. Assessment Report 2008;44(April):1\u201312."},{"issue":"1","key":"966_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-017-0601-9","volume":"12","author":"L Annemans","year":"2017","unstructured":"Annemans L, Aym\u00e9 S, Le Cam Y, Facey K, Gunther P, Nicod E, et al. Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"966_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2217\/cer.14.34","volume":"3","author":"M Schlander","year":"2014","unstructured":"Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399\u2013422 [cited 2018 May 4] Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25275236\n                    \n                  .","journal-title":"J Comp Eff Res"},{"key":"966_CR13","doi-asserted-by":"crossref","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making - An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Heal. 2016;19(1):1-13.","DOI":"10.1016\/j.jval.2015.12.003"},{"issue":"2","key":"966_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","volume":"19","author":"K Marsh","year":"2016","unstructured":"Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making--emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2016;19(2):125\u201337.","journal-title":"Value Heal J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"966_CR15","first-page":"111","volume":"1","author":"A Gilabert-Perramon","year":"2017","unstructured":"Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Merino-Montero S, Goetghebeur MMBX. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. ISPOR 20th Annu Eur Congr 4-8 Novemb 2017. Glas Scotl. 2017;1:111\u201320.","journal-title":"Glas Scotl"},{"key":"966_CR16","unstructured":"MEDES: el buscador de informaci\u00f3n m\u00e9dica en espa\u00f1ol [Internet]. [cited 2017 Jun 5]. Available from: \n                    https:\/\/www.medes.com\/Public\/Home.aspx"},{"issue":"3","key":"966_CR17","first-page":"167","volume":"56","author":"JJ Riva","year":"2012","unstructured":"Riva JJ, Malik KM, Burnie SJ, Endicott AR, Busse JW. What is your research question ? An introduction to the PICOT format for clinicians. J Chiropratic Assoc. 2012;56(3):167\u201371.","journal-title":"J Chiropratic Assoc"},{"key":"966_CR18","unstructured":"Institute of Medicine (U.S.). Committee on Standards for Systematic Reviews of Comparative Effectiveness Research., Eden J, Levit LA, Berg AO, Morton SC. Finding what works in health care : standards for systematic reviews. [cited 2018 Jun 4]. 317 p. available from: \n                    https:\/\/books.google.es\/books?id=NKcLzMnBOvcC&pg=PT228&lpg=PT228&dq=PICOTS+search+strategy&source=bl&ots=jn3PSVCdOh&sig=awGi-DPe_362P40-Oc2Im_gwFjs&hl=es&sa=X&ved=0ahUKEwjG38Ke07nbAhXD0xQKHVHiDLE4FBDoAQhLMAU#v=onepage&q=PICOTS search strategy&f=false\n                    \n                  ."},{"key":"966_CR19","unstructured":"EC. EPAR search [Internet]. [cited 2017 Feb 3]. Available from: \n                    https:\/\/www.ema.europa.eu\/en\/medicines\n                    \n                  ."},{"key":"966_CR20","unstructured":"AEMPS. TPR search [Internet]. [cited 2017 Feb 3]. Available from: \n                    https:\/\/www.aemps.gob.es\/en\/medicamentosUsoHumano\/informesPublicos\/home.htm\n                    \n                  ."},{"key":"966_CR21","unstructured":"GENESIS-SEFH. Evaluaciones GENESIS [Internet]. 2017 [cited 2017 Jan 1]. Available from: \n                    http:\/\/gruposdetrabajo.sefh.es\/genesis\/\n                    \n                  ."},{"key":"966_CR22","unstructured":"CGCOF. Botplus [Internet]. [cited 2017 Feb 3]. Available from: \n                    https:\/\/botplusweb.portalfarma.com\/\n                    \n                  ."},{"key":"966_CR23","unstructured":"EVIDEM Collaboration. A non profit organisation to promote health through efficient decisionmaking. [Internet]. [cited 2017 Jul 18]. Available from: \n                    https:\/\/evidem.org\n                    \n                  ."},{"key":"966_CR24","unstructured":"JotForm. JotForm- Template Forms [Internet]. 2017. Available from: \n                    https:\/\/www.jotform.com\/form-templates\/\n                    \n                  ."},{"key":"966_CR25","unstructured":"European Medicines Agency. Summary of Product Characteristics. Uptravi (selexipag). 2016;279."},{"key":"966_CR26","unstructured":"European Medicines Agency. Summary of product characteristics. Ventavis (iloprost). 2000;14\u20136."},{"issue":"1","key":"966_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11136-005-3513-4","volume":"15","author":"SP McKenna","year":"2006","unstructured":"McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge pulmonary hypertension outcome review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006;15(1):103\u201315.","journal-title":"Qual Life Res"},{"key":"966_CR28","unstructured":"Rabin R, Oemar M, Oppe M, Janssen B, Herdman M. EQ-5D-5L user guide. Basic Inf how to use EQ-5D-5L Instrum. 2015;(April):28."},{"key":"966_CR29","doi-asserted-by":"crossref","unstructured":"Garau M, Marsden G, Devlin N, Amedeo N, Profico A. Applying a Multi Criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab Refractory Indolent Non Hodgkin Lymphoma (iNHL). PharmacoEconomics - Open. 2017;11.","DOI":"10.1007\/s41669-017-0048-x"},{"issue":"1","key":"966_CR30","first-page":"180","volume":"12","author":"X Badia","year":"2017","unstructured":"Badia X, Poveda-Andr\u00e9s JL, Merino-Montero S. An\u00e1lisis descriptivo de los criterios usados en los informes de evaluaci\u00f3n de f\u00e1rmacos en Espa\u00f1a. Rev Espa\u00f1ola Econ la Salud [Internet]. 2017;12(1):180\u201391 Available from: \n                    http:\/\/www.economiadelasalud.com\/pdf\/V12N1\/Originales03_EvaluacionesMCDA.pdf\n                    \n                  .","journal-title":"Rev Espa\u00f1ola Econ la Salud [Internet]"},{"key":"966_CR31","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Real Decreto legislativo 1\/2015 [Internet]. 2015. Available from: \n                    https:\/\/www.boe.es\/boe\/dias\/2015\/07\/25\/pdfs\/BOE-A-2015-8343.pdf\n                    \n                  ."},{"key":"966_CR32","doi-asserted-by":"crossref","unstructured":"Gilabert-Perramon A, Betolaza J, March J, Esp\u00edn J, Merino-Montero S, Gil A, et al. Multi-Criteria Decision Analysis (MCDA): common tools for different needs supporting healthcare decision making in Spain. ISPOR 19th Annu Eur Congr 29 October-2 Novemb 2016, Vienna; 2016.","DOI":"10.1016\/j.jval.2016.09.827"},{"issue":"1","key":"966_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12885-017-3258-9","volume":"17","author":"M Wagner","year":"2017","unstructured":"Wagner M, Khoury H, Bennetts L, Berto P, Ehreth J, Badia X, et al. Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA. BMC Cancer. 2017;17(1):272 [cited 2018 Apr 16] Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28412971\n                    \n                  .","journal-title":"BMC Cancer"},{"key":"966_CR34","unstructured":"PRISMA Flow Diagram. [cited 2017 Aug 4]. Available from: \n                    http:\/\/prisma-statement.org\/prismastatement\/flowdiagram.aspx\n                    \n                  ."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0966-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T19:13:29Z","timestamp":1575918809000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0966-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0966-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required as no animals nor humans were involved in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors have consented to publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"220"}}